Close

Salarius Pharmaceuticals, Inc. (SLRX) Reports Complete Dose-Escalation Stage of Phase 1/2 RP2D Clinical Trial in R/R Ewing Sarcoma Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/20/2024

1. NFLX
2. TSM
3. ISRG
4. TSLA
5. SPY
6. INFY
7. SNV
8. SMCI
9. SLB
10. PPG


Go back to Salarius Pharmaceuticals, Inc. (SLRX) Reports Complete Dose-Escalation Stage of Phase 1/2 RP2D Clinical Trial in R/R Ewing Sarcoma Patients

Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

February 17, 2021 7:30 AM EST

Seclidemstat safety profile affirmed; Recommended Phase 2 dose established

Demonstrated preliminary evidence of seclidemstat drug activity in subset of Ewing-related sarcoma patients

HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) --  Salarius Pharmaceuticals, Inc. (Nasdaq:... More